drugset / Trial / NCT07625293
DB-3Q for the Treatment of Medically Refractory Crohn's Disease
RandomizedSequentialDouble-blindTreatment
Summary
This research study is studying DB-3Q as a possible treatment for medically refractory Crohn's disease. The purpose of this study is to research and evaluate safety and effectiveness of the administration of bone marrow mesenchymal stem cell (bmMSC) derived extracellular vesicles product, DB-3Q, the study drug for Crohn's disease.
Timeline
- Start
- 2026-06
- Primary completion
- 2027-06
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DB-3Q | Other / unclassified | 15 ml | Intravenous |
| Subject | DB-3Q | Other / unclassified | 30 ml | Intravenous |
| Subject | DB-3Q | Other / unclassified | 45 ml | Intravenous |